MedTrace Logo

Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160)

NCT05304364 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-02-13

No results posted yet for this study

Summary

This is an Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Naltrexone HCL to DLP-160 (Naltrexone implant) to Intramuscular Vivitrol®

Conditions

  • Opiod Use Disorder

Interventions

COMBINATION_PRODUCT

Combination Product: Naltrexone

Naltrexone Implant

Sponsors & Collaborators

  • Delpor, Inc.

    lead INDUSTRY

Principal Investigators

  • Alex Choo, MD · CMAX

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-22
Primary Completion
2022-10-21
Completion
2022-11-19

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05304364 on ClinicalTrials.gov